REVIEWER: James F. Kneece, director of financial planning and analysis for GTC Biotherapeutics, Inc.
BACKGROUND: GTC is a leader in the development, production and commercialization of therapeutic proteins through transgenic animal technology. GTC's ATryn, a recombinant form of human antithrombin, is undergoing review for market authorization in Europe. Subject to satisfactory approval, GTC will be the first company to commercially offer a transgenically produced product. GTC's technology is also used to develop transgenic production of its partners' proprietary products.
Register or login for access to this item and much more
All Information Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access